60¢sixtycents

Mineralys Therapeutics, Inc.MLYS

$24.63-0.50 (-1.99%)
NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap
$2B
Mid-cap
+2582%
2023 — today
10-Year Price
+69%
2023 — today
52-Week Range
$12.87$47.33
Current $24.63· 34%

Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.

Valuation in context

P/E ratio
-12.0
N/A
Not meaningful — company is unprofitable
P/B ratio
3.2
Historically pricey
Historically pricey — last 10 years
FCF Yield
-6.7%
Historically high
Historically high relative to the last 10 years
Free · No credit card needed

Get alerted when MLYS is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.